Search results
Search for "antineoplastic" in Full Text gives 24 result(s) in Beilstein Journal of Organic Chemistry.
Harnessing unprotected deactivated amines and arylglyoxals in the Ugi reaction for the synthesis of fused complex nitrogen heterocycles
- Javier Gómez-Ayuso,
- Pablo Pertejo,
- Tomás Hermosilla,
- Israel Carreira-Barral,
- Roberto Quesada and
- María García-Valverde
Beilstein J. Org. Chem. 2024, 20, 1758–1766, doi:10.3762/bjoc.20.154
- search of new bioactive compounds, as evidenced by the fact that they are present in many marketed drugs [1][2]. These substructures are found fused with other heterocycles in many cases, as illustrated by the antineoplastic dibromophakellstatin [3][4][5][6], the CDK inhibitor trilaciclib [7] or the
Graphical Abstract
Figure 1: Fused heterocycles containing the piperazine and diazepine core.
Scheme 1: Synthesis of benzodiazepinones 5 from anthranilic acid derivatives.
Scheme 2: Diastereoselective one-pot synthesis of benzodiazepinones 6.
Scheme 3: Synthesis of bis-1,4-benzodiazepines 7.
Scheme 4: Synthesis of benzodiazepinone 5c and pyrrolobenzodiazepinone 8 from anthranilic acid and 3-bromopro...
Scheme 5: Synthesis of pyrrolopiperazinones 9 from pyrrole and indole carboxylic acids.
Scheme 6: Synthesis of pyrrolopiperazinones 10 from N-phenylglicine.
Figure 2: X-ray diffraction structures of pyrrolopiperazinones 9a (left) and 10a (right). The thermal ellipso...
Scheme 7: Synthesis of pyrrolopiperazinone 11 using (S)-α-methylbenzylamine.
Scheme 8: Proposed mechanism in the spontaneous cyclization of Ugi adducts obtained from arylglyoxals and dea...
Scheme 9: Synthesis of pyrrolopiperazinoquinazolines 13.
Scheme 10: Synthesis of piperazinoquinazoline 14.
Scheme 11: Synthesis of dipyrrolopiperazinones 12.
Figure 3: X-ray diffraction structure of dipyrrolopiperazinone 12c. The thermal ellipsoid plot (Olex2) is at ...
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Combretastatins D series and analogues: from isolation, synthetic challenges and biological activities
- Jorge de Lima Neto and
- Paulo Henrique Menezes
Beilstein J. Org. Chem. 2023, 19, 399–427, doi:10.3762/bjoc.19.31
- characterized as an oxa[1.7]meta-paracyclophane framework. In the literature we can find reports about the isolation/synthesis of combretastatins D and their analogues which showed different biological activities, e.g., antineoplastic, anti-inflammatory, and α-glucosidase inhibition [13][14][15]. The presence
Graphical Abstract
Figure 1: Structures of some members of the combretastatin D series, corniculatolides, and isocorniculatolide...
Scheme 1: Biosynthetic pathway proposed by Pettit and co-workers.
Scheme 2: Biosynthetic pathway towards corniculatolides or isocorniculatolides proposed by Ponnapalli and co-...
Scheme 3: Retrosynthetic approaches.
Scheme 4: Attempt of total synthesis of 2 by Boger and co-workers employing the Mitsunobu approach [27].
Scheme 5: Total synthesis of combretastatin D-2 (2) reported by Boger and co-workers employing an intramolecu...
Scheme 6: Formal synthesis of combretastatin D-2 (2) by Deshpande and co-workers using the Mitsunobu conditio...
Scheme 7: Total synthesis of combretastatin D-2 (2) by Rychnovsky and Hwang [36].
Scheme 8: Divergent synthesis of (±)-1 form combretastatin D-2 (2) by Rychnovsky and Hwang [36].
Scheme 9: Enantioselective synthesis of 1 by Rychnovsky and Hwang employing Jacobsen catalyst [41].
Scheme 10: Synthesis of fragment 57 by Couladouros and co-workers [43,45].
Scheme 11: Formal synthesis of compound 2 by Couladouros and co-workers [43,45].
Scheme 12: Synthesis of fragment 66 by Couladouros and co-workers [44,45].
Scheme 13: Synthesis of fragment 70 by Couladouros and co-workers [44,45].
Scheme 14: Synthesis of fragment 77 by Couladouros and co-workers [44,45].
Scheme 15: Synthesis of combretastatins 1 and 2 by Couladouros and co-workers [44,45].
Scheme 16: Formal synthesis of compound 2 by Gangakhedkar and co-workers [48].
Scheme 17: Synthesis of fragment 14 by Cousin and co-workers [50].
Scheme 18: Synthesis of fragment 91 by Cousin and co-workers [50].
Scheme 19: Formal synthesis of compound 2 by Cousin and co-workers [50].
Scheme 20: Synthesis of 2 diolide by Cousin and co-workers [50].
Scheme 21: Synthesis of combretastatin D-4 (4) by Nishiyama and co-workers [54].
Scheme 22: Synthesis of fragment 112 by Pettit and co-workers [55].
Scheme 23: Synthesis of fragment 114 by Pettit and co-workers [55].
Scheme 24: Attempt to the synthesis of compound 2 by Pettit and co-workers [55].
Scheme 25: Synthesis of combretastatin-D2 (2) starting from isovanilin (80) by Pettit and co-workers [55].
Scheme 26: Attempted synthesis of combretastatin-D2 (2) derivatives through an SNAr approach [55].
Scheme 27: Synthesis of combretastatin D-4 (4) by Pettit and co-workers [55].
Scheme 28: Synthesis of combretastatin D-2 (2) by Harras and co-workers [57].
Scheme 29: Synthesis of combretastatin D-4 (4) by Harras and co-workers [57].
Scheme 30: Formal synthesis of combretastatin D-1 (1) by Harras and co-workers [57].
Scheme 31: Synthesis of 11-O-methylcorniculatolide A (5) by Raut and co-workers [69].
Scheme 32: Synthesis of isocorniculatolide A (7) and O-methylated isocorniculatolide A 8 by Raut and co-worker...
Scheme 33: Synthesis of isocorniculatolide B (10) and hydroxyisocorniculatolide B 175 by Kim and co-workers [71].
Scheme 34: Synthesis of compound 9, 178, and 11 by Kim and co-workers [71].
Scheme 35: Synthesis of combretastatin D-2 prodrug salts [55].
Figure 2: ED50 values of the combretastatin D family against murine P388 lymphocytic leukemia cell line (appr...
Figure 3: IC50 of compounds against α-glucosidase [19].
Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases
- Julia N. Artsemyeva,
- Ekaterina A. Remeeva,
- Tatiana N. Buravskaya,
- Irina D. Konstantinova,
- Roman S. Esipov,
- Anatoly I. Miroshnikov,
- Natalia M. Litvinko and
- Igor A. Mikhailopulo
Beilstein J. Org. Chem. 2020, 16, 2607–2622, doi:10.3762/bjoc.16.212
- wearisome [5][66]. This evidence prompted us to engage in the design and development of an efficient biotechnological synthetic route. Cladribine has been known for over 30 years as antineoplastic (Leustatine®) and anti-multiple sclerosis agent (for a few leading references, see [67][68][69][70]). The
Graphical Abstract
Scheme 1: General scheme of the suggested synthesis of nucleosides employing the enzymatic phosphorolysis of ...
Figure 1: Phosphorolysis (5.0 mM K-phosphate buffer, pH 7.0; 23 °C) of Ara-U and thymidine (Thd) catalyzed by...
Scheme 2: Transarabinosylation of O6-methylguanine (OMG) employing Ara-U as a donor of the Ara-1Pi (1:1.5 mol...
Figure 2: Optimized conditions of phosphorolysis of Ara-U: 0.20 mmol of Ara-U in distilled water (30 mL) cont...
Scheme 3: Synthesis of nelarabine with intermediate preparation of crude Ara-1Pi.
Scheme 4: Synthesis of kinetin riboside with intermediate preparation of crude Rib-1Pi.
Isolation of fungi using the diffusion chamber device FIND technology
- Benjamin Libor,
- Henrik Harms,
- Stefan Kehraus,
- Ekaterina Egereva,
- Max Crüsemann and
- Gabriele M. König
Beilstein J. Org. Chem. 2019, 15, 2191–2203, doi:10.3762/bjoc.15.216
- antibiotics (e.g., cephalosporins), immunosuppressants (e.g., mycophenolic acid) and immunomodulators (e.g., fingolimod), as well as cholesterol lowering agents (statins). Generally, fungal metabolites were shown to have antiviral, cytotoxic, antineoplastic, cardiovascular, anti-inflammatory, immune
Graphical Abstract
Scheme 1: Design and functional parts of the FIND technology.
Scheme 2: Isolation of fungal strains with the FIND technology. 1. Collection of terrestrial or marine sample...
Figure 1: Secondary metabolites isolated from H. cf. alpina.
Figure 2: a) Significant 1H,1H-COSY and 1H,13C-HMBC correlations for compounds 1 and 2. b) Key NOESY correlat...
Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids
- Eszter Lajkó,
- Sarah Spring,
- Rózsa Hegedüs,
- Beáta Biri-Kovács,
- Sven Ingebrandt,
- Gábor Mező and
- László Kőhidai
Beilstein J. Org. Chem. 2018, 14, 2495–2509, doi:10.3762/bjoc.14.226
- internalize into the cells by receptor-mediated manner, where the attached drug should be released from the conjugate in order to exert its antineoplastic activity [1]. The first GnRH-drug hybrids were developed by Schally and co-workers [9]. One of their most efficient conjugates was the zoptarelin
- able to deliver Dau to A2058 human melanoma cells and provide its antineoplastic activity. The presence of short-chain fatty acid containing Lys in position 4 was shown to be accompanied by an increased cellular uptake and a higher long-term cytotoxic activity mediated via a PI3K-dependent signaling
Graphical Abstract
Figure 1: Schematic structure of Dau-conjugated GnRH-III or its derivatives containing 4Lys with acetyl or bu...
Figure 2: Cellular uptake of Dau–GnRH-III conjugates and free daunorubicin (Dau) by A2058 cells. Cellular upt...
Figure 3: Short-term growth inhibitory effects of the conjugates and daunorubicin (Dau) on A2058 cells. The m...
Figure 4: Effects of conjugates and daunorubicin (Dau) on cell cycle progression of A2058 melanoma cells. The...
Figure 5: Effects of the conjugates and daunorubicin (Dau) on melanoma cell adhesion. The Delta CI (Delta Cel...
Figure 6: Chemotactic effects of Dau–GnRH-III conjugates on A2058 cell line. The ‘Chemotaxis index’ (Chtx. in...
Figure 7: Effects of GnRH-III(Dau=Aoa) (a–c), [4Lys(Ac)]-GnRH-III(Dau=Aoa) (d–f) and [4Lys(Bu)]-GnRH-III(Dau=...
Figure 8: Schematic representation of the proposed mechanisms of the effects of GnRH-III conjugates containin...
Anomeric modification of carbohydrates using the Mitsunobu reaction
- Julia Hain,
- Patrick Rollin,
- Werner Klaffke and
- Thisbe K. Lindhorst
Beilstein J. Org. Chem. 2018, 14, 1619–1636, doi:10.3762/bjoc.14.138
- addition, 4 was also converted with the phyllanthostatin aglycone 8 to give 10 with inversion of anomeric configuration. Extension of this work to other more complex antineoplastic glycosyl esters was successfully investigated by the same group [30][31][32][33][34]. De Mesmaeker et al. reported the
Graphical Abstract
Scheme 1: Left: The Mitsunobu reaction is essentially a nucleophilic substitution of alcohols occurring with ...
Scheme 2: Mechanistic considerations on the Mitsunobu reaction with carbohydrate hemiacetals (depicted in sim...
Scheme 3: Anomeric esterification using the Mitsunobu procedure [29].
Scheme 4: Conversion of allyl glucuronate into various 1-O-esterified allyl glucuronates using anomeric Mitsu...
Scheme 5: Synthesis of anomeric glycosyl esters as substrates for Au-catalyzed glycosylation [40].
Scheme 6: Correlation between pKa value of the employed acids (or alcohol) and the favoured anomeric configur...
Scheme 7: Synthesis of the β-mannosyl phosphates for the synthesis of HBP 43 by anomeric phosphorylation acco...
Scheme 8: Synthesis of phenyl glycosides 44 and 45 from unprotected sugars [24].
Scheme 9: Synthesis of azobenzene mannosides 47 and 48 without protecting group chemistry [46].
Scheme 10: Synthesis of various aryl sialosides using Mitsunobu glycosylation [25].
Scheme 11: Mitsunobu synthesis of different jadomycins [54,55]. BOM: benzyloxymethyl.
Scheme 12: Stereoselectivity in the Mitsunobu synthesis of catechol glycosides in the gluco- and manno-series [56]....
Scheme 13: Formation of a 1,2-cis glycoside 80 assisted by steric hindrance of the β-face of the disaccharide ...
Scheme 14: Stereoselective β-D-mannoside synthesis [60].
Scheme 15: TIPS-assisted synthesis of 1,2-cis arabinofuranosides [63]. TIPS: triisopropylsilyl.
Scheme 16: The Mitsunobu reaction with glycals leads to interesting rearrangement products [69].
Scheme 17: Synthesis of disaccharides using mercury(II) bromide as co-activator in the Mitsunobu reaction [75].
Scheme 18: Synthesis of various fructofuranosides according to Mitsunobu and proposed neighbouring group parti...
Scheme 19: The Mitsunobu reaction allows stereoslective acetalization of dihydroartemisinin [77].
Scheme 20: Synthesis of alkyl thioglycosides by Mitsunobu reaction [81].
Scheme 21: Preparation of iminoglycosylphthalimide 115 from 114 [85].
Scheme 22: Mitsunobu reaction as a key step in the total synthesis of aurantoside G [87].
Scheme 23: Utilization of an N–H acid in the Mitsunobu reaction [88].
Scheme 24: Mitsunobu reaction with 1H-tetrazole [89].
Scheme 25: Formation of a rebeccamycin analogue using the Mitsunobu reaction [101].
Scheme 26: Synthesis of carbohydrates with an alkoxyamine bond [114].
Scheme 27: Synthesis of glycosyl fluorides and glycosyl azides according to Mitsunobu [118,119].
Scheme 28: Anomeric oxidation under Mitsunobu conditions [122].
Glycosylation reactions mediated by hypervalent iodine: application to the synthesis of nucleosides and carbohydrates
- Yuichi Yoshimura,
- Hideaki Wakamatsu,
- Yoshihiro Natori,
- Yukako Saito and
- Noriaki Minakawa
Beilstein J. Org. Chem. 2018, 14, 1595–1618, doi:10.3762/bjoc.14.137
- . Design of potential antineoplastic nucleosides. Concept of the Pummerer-type glycosylation and hypervalent iodine-mediated glycosylation. Speculated mechanism of oxidative glycosylation mediated by hypervalent iodine. Concept of the oxidative coupling reaction applicable to the synthesis of carbocyclic
Graphical Abstract
Figure 1: Design of potential antineoplastic nucleosides.
Scheme 1: Synthesis of 4’-thioDMDC.
Scheme 2: Synthesis of 4’-thioribonucleosides by Minakawa and Matsuda.
Scheme 3: Synthesis of 4’-thioribonucleosides by Yoshimura.
Figure 2: Concept of the Pummerer-type glycosylation and hypervalent iodine-mediated glycosylation.
Scheme 4: Oxidative glycosylation of 4-thioribose mediated by hypervalent iodine.
Figure 3: Speculated mechanism of oxidative glycosylation mediated by hypervalent iodine.
Scheme 5: Synthesis of purine 4’-thioribonucleosides using hypervalent iodine-mediated glycosylation.
Scheme 6: Unexpected glycosylation of a thietanose derivative.
Scheme 7: Speculated mechanism of the ring expansion of a thietanose derivative.
Scheme 8: Synthesis of thietanonucleosides using the Pummerer-type glycosylation.
Scheme 9: First synthesis of 4’-selenonucleosides.
Scheme 10: The Pummerer-type glycosylation of 4-selenoxide 74.
Scheme 11: Synthesis of purine 4’-selenonucleosides using hypervalent iodine-mediated glycosylation.
Figure 4: Concept of the oxidative coupling reaction applicable to the synthesis of carbocyclic nucleosides.
Scheme 12: Oxidative coupling reaction mediated by hypervalent iodine.
Scheme 13: Synthesis of cyclohexenyl nucleosides using an oxidative coupling reaction.
Figure 5: Concept of the oxidative coupling reaction of glycal derivatives.
Scheme 14: Oxidative coupling reaction of silylated uracil and DHP using hypervalent iodine.
Scheme 15: Proposed mechanism of the oxidative coupling reaction mediated by hypervalent iodine.
Figure 6: Synthesis of 2’,3’-unsaturated nucleosides using hypervalent iodine and a co-catalyst.
Scheme 16: Synthesis of dihydropyranonucleoside.
Scheme 17: Synthesis of acetoxyacetals using hypervalent iodine and addition of silylated base.
Scheme 18: One-pot fragmentation-nucleophilic additions mediated by hypervalent iodine.
Figure 7: The reaction of thioglycoside with hypervalent iodine in the presence of Lewis acids.
Scheme 19: Synthesis of disaccharides employing thioglycosides under an oxidative coupling reaction mediated b...
Scheme 20: Synthesis of disaccharides using disarmed thioglycosides by hypervalent iodine-mediated glycosylati...
Scheme 21: Glycosylation using aryl(trifluoroethyl)iodium triflimide.
Figure 8: Expected mechanism of hypervalent iodine-mediated glycosylation with glycals.
Scheme 22: Synthesis of oligosaccharides by hypervalent iodine-mediated glycosylation with glycals.
Scheme 23: Synthesis of 2-deoxy amino acid glycosides.
Figure 9: Rationale for the intramolecular migration of the amino acid unit.
One hundred years of benzotropone chemistry
- Arif Dastan,
- Haydar Kilic and
- Nurullah Saracoglu
Beilstein J. Org. Chem. 2018, 14, 1120–1180, doi:10.3762/bjoc.14.98
- ][18][19][20][21][22][23] (isolated from the heartwood and essential oils of trees of the family Cupressaceae), to complex macrocyclic analogues, such as harringtonolide (5) [24][25][26], which was found to have antineoplastic and antiviral properties, and caulersin (6) [26], which is a biologically
Graphical Abstract
Scheme 1: Tropone (1), tropolone (2) and their resonance structures.
Figure 1: Natural products containing a tropone nucleus.
Figure 2: Possible isomers 11–13 of benzotropone.
Scheme 2: Synthesis of benzotropones 11 and 12.
Scheme 3: Oxidation products of benzotropylium fluoroborate (16).
Scheme 4: Oxidation of 7-bromo-5H-benzo[7]annulene (22).
Scheme 5: Synthesis of 4,5-benzotropone (11) using o-phthalaldehyde (27).
Scheme 6: Synthesis of 4,5-benzotropone (11) starting from oxobenzonorbornadiene 31.
Scheme 7: Acid-catalyzed cleavage of oxo-bridge of 34.
Scheme 8: Synthesis of 4,5-benzotropone (11) from o-xylylene dibromide (38).
Scheme 9: Synthesis of 4,5-benzotropone (11) via the carbene adduct 41.
Scheme 10: Heck coupling strategy for the synthesis of 11.
Scheme 11: Synthesis of benzofulvalenes via carbonyl group of 4,5-benzotropone (11).
Figure 3: Some cycloheptatrienylium cations.
Scheme 12: Synthesis of condensation product 63 and its subsequent oxidative cyclization products.
Figure 4: A novel series of benzo[7]annulenes prepared from 4,5-benzotropone (11).
Scheme 13: Preparation of substituted benzo[7]annulene 72 using the Mukaiyama-Michael reaction.
Figure 5: Possible benzo[7]annulenylidenes 73–75.
Scheme 14: Thermal and photochemical decomposition of 7-diazo-7H-benzo[7]annulene (76) and the trapping of int...
Scheme 15: Synthesis of benzoheptafulvalene 86.
Scheme 16: Synthesis of 7-(diphenylmethylene)-7H-benzo[7]annulene (89).
Scheme 17: Reaction of 4,5-benzotropone (11) with dimethyl diazomethane.
Scheme 18: Synthesis of dihydrobenzomethoxyazocine 103.
Scheme 19: Synthesis and reducibility of benzo-homo-2-methoxyazocines.
Scheme 20: Synthesis of 4,5-benzohomotropones 104 and 115 from 4,5-benzotropones 11 and 113.
Scheme 21: A catalytic deuterogenation of 4,5-benzotropone (11) and synthesis of 5-monosubstituted benzo[7]ann...
Scheme 22: Synthesis of methyl benzo[7]annulenes 131 and 132.
Scheme 23: Ambident reactivity of halobenzo[7]annulenylium cations 133a/b.
Scheme 24: Preparation of benzo[7]annulenylidene–iron complexes 147.
Scheme 25: Synthesis of 1-ethynylbenzotropone (150) and the etheric compound 152 from 4,5-benzotropone (11) wi...
Scheme 26: Thermal decomposition of 4,5-benzotropone (11).
Scheme 27: Reaction of 4,5-benzotropone (11) with 1,2-ethanediol and 1,2-ethanedithiol.
Scheme 28: Conversions of 1-benzosuberone (162) to 2,3-benzotropone (12).
Scheme 29: Synthesis strategies for 2,3-bezotropone (12) using 1-benzosuberones.
Scheme 30: Oxidation-based synthesis of 2,3-benzotropone (12) via 1-benzosuberone (162).
Scheme 31: Synthesis of 2,3-benzotropone (12) from α-tetralone (171) via ring-expansion.
Scheme 32: Preparation of 2,3-benzotropone (12) by using of benzotropolone 174.
Figure 6: Benzoheptafulvenes as condensation products of 2,3-benzotropone (12).
Scheme 33: Conversion of 2,3-benzotropone (12) to tosylhydrazone salt 182 and gem-dichloride 187.
Figure 7: Benzohomoazocines 191–193 and benzoazocines 194–197.
Scheme 34: From 2,3-benzotropone (12) to carbonium ions 198–201.
Scheme 35: Cycloaddition reactions of 2,3-benzotropone (12).
Scheme 36: Reaction of 2,3-benzotropone (12) with various reagents and compounds.
Figure 8: 3,4-Benzotropone (13) and its resonance structure.
Scheme 37: Synthesis of 6,7-benzobicyclo[3.2.0]hepta-3,6-dien-2-one (230).
Figure 9: Photolysis and thermolysis products of 230.
Figure 10: Benzotropolones and their tautomeric structures.
Scheme 38: Synthesis strategies of 4,5-benzotropolone (238).
Scheme 39: Synthesis protocol for 2-hydroxy-4,5-benzotropone (238) using oxazole-benzo[7]annulene 247.
Figure 11: Some quinoxaline and pyrazine derivatives 254–256 prepared from 4,5-benzotropolone (238).
Scheme 40: Nitration product of 4,5-benzotropolone (238) and its isomerization to 1-nitro-naphthoic acid (259)....
Scheme 41: Synthesis protocol for 6-hydroxy-2,3-benzotropone (239) from benzosuberone (162).
Scheme 42: Various reactions via 6-hydroxy-2,3-benzotropone (239).
Scheme 43: Photoreaction of 6-hydroxy-2,3-benzotropone (239).
Scheme 44: Synthesis of 7-hydroxy-2,3-benzotropone (241) from benzosuberone (162).
Scheme 45: Synthesis strategy for 7-hydroxy-2,3-benzotropone (241) from ketone 276.
Scheme 46: Synthesis of 7-hydroxy-2,3-benzotropone (241) from β-naphthoquinone (280).
Scheme 47: Synthesis of 7-hydroxy-2,3-benzotropone (241) from bicyclic endoperoxide 213.
Scheme 48: Synthesis of 7-hydroxy-2,3-benzotropone (241) by ring-closing metathesis.
Figure 12: Various monosubstitution products 289–291 of 7-hydroxy-2,3-benzotropone (241).
Scheme 49: Reaction of 7-hydroxy-2,3-benzotropone (241) with various reagents.
Scheme 50: Synthesis of 4-hydroxy-2,3-benzotropones 174 and 304 from diketones 300/301.
Scheme 51: Catalytic hydrogenation of diketones 300 and 174.
Scheme 52: Synthesis of halo-benzotropones from alkoxy-naphthalenes 306, 307 and 310.
Figure 13: Unexpected byproducts 313–315 during synthesis of chlorobenzotropone 309.
Figure 14: Some halobenzotropones and their cycloadducts.
Scheme 53: Multisep synthesis of 2-chlorobenzotropone 309.
Scheme 54: A multistep synthesis of 2-bromo-benzotropone 26.
Scheme 55: A multistep synthesis of bromo-2,3-benzotropones 311 and 316.
Scheme 56: Oxidation reactions of 8-bromo-5H-benzo[7]annulene (329) with some oxidants.
Scheme 57: Synthesis of 2-bromo-4,5-benzotropone (26).
Scheme 58: Synthesis of 6-chloro-2,3-benzotropone (335) using LiCl and proposed intermediate 336.
Scheme 59: Reaction of 7-bromo-2,3-benzotropone (316) with methylamine.
Scheme 60: Reactions of bromo-2,3-benzotropones 26 and 311 with dimethylamine.
Scheme 61: Reactions of bromobenzotropones 311 and 26 with NaOMe.
Scheme 62: Reactions of bromobenzotropones 26 and 312 with t-BuOK in the presence of DPIBF.
Scheme 63: Cobalt-catalyzed reductive cross-couplings of 7-bromo-2,3-benzotropone (316) with cyclic α-bromo en...
Figure 15: Cycloadduct 357 and its di-π-methane rearrangement product 358.
Scheme 64: Catalytic hydrogenation of 2-chloro-4,5-benzotropone (311).
Scheme 65: Synthesis of dibromo-benzotropones from benzotropones.
Scheme 66: Bromination/dehydrobromination of benzosuberone (162).
Scheme 67: Some transformations of isomeric dibromo-benzotropones 261A/B.
Scheme 68: Transformations of benzotropolone 239B to halobenzotropolones 369–371.
Figure 16: Bromobenzotropolones 372–376 and 290 prepared via bromination/dehydrobromination strategy.
Scheme 69: Synthesis of some halobenzotropolones 289, 377 and 378.
Figure 17: Bromo-chloro-derivatives 379–381 prepared via chlorination.
Scheme 70: Synthesis of 7-iodo-3,4-benzotropolone (382).
Scheme 71: Hydrogenation of bromobenzotropolones 369 and 370.
Scheme 72: Debromination reactions of mono- and dibromides 290 and 375.
Figure 18: Nitratation and oxidation products of some halobenzotropolenes.
Scheme 73: Azo-coupling reactions of some halobenzotropolones 294, 375 and 378.
Figure 19: Four possible isomers of dibenzotropones 396–399.
Figure 20: Resonance structures of tribenzotropone (400).
Scheme 74: Two synthetic pathways for tribenzotropone (400).
Scheme 75: Synthesis of tribenzotropone (400) from dibenzotropone 399.
Scheme 76: Synthesis of tribenzotropone (400) from 9,10-phenanthraquinone (406).
Scheme 77: Synthesis of tribenzotropone (400) from trifluoromethyl-substituted arene 411.
Figure 21: Dibenzosuberone (414).
Figure 22: Reduction products 415 and 416 of tribenzotropone (400).
Figure 23: Structures of tribenzotropone dimethyl ketal 417 and 4-phenylfluorenone (412) and proposed intermed...
Figure 24: Structures of benzylidene- and methylene-9H-tribenzo[a,c,e][7]annulenes 419 and 420 and chiral phos...
Figure 25: Structures of tetracyclic alcohol 422, p-quinone methide 423 and cation 424.
Figure 26: Structures of host molecules 425–427.
Scheme 78: Synthesis of non-helical overcrowded derivatives syn/anti-431.
Figure 27: Hexabenzooctalene 432.
Figure 28: Structures of possible eight isomers 433–440 of naphthotropone.
Scheme 79: Synthesis of naphthotropone 437 starting from 1-phenylcycloheptene (441).
Scheme 80: Synthesis of 10-hydroxy-11H-cyclohepta[a]naphthalen-11-one (448) from diester 445.
Scheme 81: Synthesis of naphthotropone 433.
Scheme 82: Synthesis of naphthotropones 433 and 434 via cycloaddition reaction.
Scheme 83: Synthesis of naphthotropone 434 starting from 452.
Figure 29: Structures of tricarbonyl(tropone)irons 458, and possible cycloadducts 459.
Scheme 84: Synthesis of naphthotropone 436.
Scheme 85: Synthesis of precursor 465 for naphthotropone 435.
Scheme 86: Generation of naphthotropone 435 from 465.
Figure 30: Structures of tropylium cations 469 and 470.
Figure 31: Structures of tropylium ions 471+.BF4−, 472+.BF4−, and 473+.BF4−.
Scheme 87: Synthesis of tropylium ions 471+.BF4− and 479+.ClO4−.
Scheme 88: Synthesis of 1- and 2-methylanthracene (481 and 482) via carbene–carbene rearrangement.
Figure 32: Trapping products 488–490.
Scheme 89: Generation and chemistry of a naphthoannelated cycloheptatrienylidene-cycloheptatetraene intermedia...
Scheme 90: Proposed intermediates and reaction pathways for adduct 498.
Scheme 91: Exited-state intramolecular proton transfer of 505.
Figure 33: Benzoditropones 506 and 507.
Scheme 92: Synthesis of benzoditropone 506e.
Scheme 93: Synthetic approaches for dibenzotropone 507 via tropone (1).
Scheme 94: Formation mechanisms of benzoditropone 507 and 516 via 515.
Scheme 95: Synthesis of benzoditropones 525 and 526 from pyromellitic dianhydride (527).
Figure 34: Possible three benzocyclobutatropones 534–536.
Scheme 96: Synthesis of benzocyclobutatropones 534 and 539.
Scheme 97: Synthesis attempts for benzocyclobutatropone 545.
Scheme 98: Generation and trapping of symmetric benzocyclobutatropone 536.
Scheme 99: Synthesis of chloro-benzocyclobutatropone 552 and proposed mechanism of fluorenone derivatives.
Scheme 100: Synthesis of tropolone analogue 559.
Scheme 101: Synthesis of tropolones 561 and 562.
Figure 35: o/p-Tropoquinone rings (563 and 564) and benzotropoquinones (565–567).
Scheme 102: Synthesis of benzotropoquinone 566.
Scheme 103: Synthesis of benzotropoquinone 567 via a Diels–Alder reaction.
Figure 36: Products 575–577 through 1,2,3-benzotropoquinone hydrate 569.
Scheme 104: Structures 578–582 prepared from tropoquinone 567.
Figure 37: Two possible structures 583 and 584 for dibenzotropoquinone, and precursor compound 585 for 583.
Scheme 105: Synthesis of saddle-shaped ketone 592 using dibenzotropoquinone 584.
An overview of recent advances in duplex DNA recognition by small molecules
- Sayantan Bhaduri,
- Nihar Ranjan and
- Dev P. Arya
Beilstein J. Org. Chem. 2018, 14, 1051–1086, doi:10.3762/bjoc.14.93
- the past few years. Keywords: alkylators; antibiotic; anticancer; antineoplastic; antiproliferative; DNA recognition; groove binders; hairpin polyamides; Hoechst 33258; intercalators; Review 1. Introduction DNA is one of the central components of cellular machinery and storage unit of genetic
- fashion, they further reported a series of novel hybrids by tethering distamycin A with the antineoplastic agent uramustine via a flexible polymethylene chain of variable length (n = 1 to 6) in order to test their DNA binding affinity and cytotoxicity [57]. It has been observed that hybrid conjugates 8, 9
Graphical Abstract
Figure 1: A figure showing the hydrogen bonding patterns observed in (a) duplex (b) triplex and (c) quadruple...
Figure 2: (a) Portions of MATα1–MATα2 are shown contacting the minor groove of the DNA substrate. Key arginin...
Figure 3: Chemical structures of naturally occurring and synthetic hybrid minor groove binders.
Figure 4: Synthetic structural analogs of distamycin A by replacing one or more pyrrole rings with other hete...
Figure 5: Pictorial representation of the binding model of pyrrole–imidazole (Py/Im) polyamides based on the ...
Figure 6: Chemical structures of synthetic “hairpin” pyrrole–imidazole (Py/Im) conjugates.
Figure 7: (a) Minor groove complex formation between DNA duplex and 8-ring cyclic Py/Im polyamide (conjugate ...
Figure 8: Telomere-targeting tandem hairpin Py/Im polyamides 23 and 24 capable of recognizing >10 base pairs; ...
Figure 9: Representative examples of recently developed DNA minor groove binders.
Figure 10: Chemical structures of bisbenzamidazoles Hoechst 33258 and 33342 and their synthetic structural ana...
Figure 11: Chemical structures of bisamidines such as diminazene, DAPI, pentamidine and their synthetic struct...
Figure 12: Representative examples of recently developed bisamidine derivatives.
Figure 13: Chemical structures of chromomycin, mithramycin and their synthetic structural analogs 91 and 92.
Figure 14: Chemical structures of well-known naturally occurring DNA binding intercalators.
Figure 15: Naturally occurring indolocarbazole rebeccamycin and its synthetic analogs.
Figure 16: Representative examples of naturally occurring and synthetic derivatives of DNA intercalating agent...
Figure 17: Several recent synthetic varieties of DNA intercalators.
Figure 18: Aminoglycoside (neomycin)–Hoechst 33258/intercalator conjugates.
Figure 19: Chemical structures of triazole linked neomycin dimers and neomycin–bisbenzimidazole conjugates.
Figure 20: Representative examples of naturally occurring and synthetic analogs of DNA binding alkylating agen...
Figure 21: Chemical structures of naturally occurring and synthetic analogs of pyrrolobenzodiazepines.
Superstructures with cyclodextrins: Chemistry and applications IV
- Gerhard Wenz
Beilstein J. Org. Chem. 2017, 13, 2157–2159, doi:10.3762/bjoc.13.215
- nanoparticles with the sensitizer Zn-phthalocyanine and the antineoplastic drug docetaxel. These materials might be applicable for dual cancer therapy [15]. Another self-assembled CD nanocarrier for the photoreactive dye squaraine that is useful for photodynamic therapy is described in this Thematic Series [16
Strategies in megasynthase engineering – fatty acid synthases (FAS) as model proteins
- Manuel Fischer and
- Martin Grininger
Beilstein J. Org. Chem. 2017, 13, 1204–1211, doi:10.3762/bjoc.13.119
- antineoplastic doxorubicin and by the antiparasitic avermectin (Figure 1a) [1]. PK are assembled from acyl-coenzyme A (acyl-CoA) units via a series of Claisen-type condensation reactions catalyzed by polyketide synthases (PKS) (Figure 1b). PKS occur as large multifunctional enzymes, termed megasynthases, which
Graphical Abstract
Figure 1: Megasynthases – chemistry and modes of action. a) Products of PKS and FAS megasynthases. b) Reactio...
Figure 2: Compartmentalization of synthesis. a) Surface depiction of fungal FAS (PDB-code: 3hmj) with the upp...
Figure 3: Strategies of megasynthase engineering. a) Mix-and-match approach: A hypothetical chimeric PKS is a...
Figure 4: Preserve-and-adapt approach with FAS. C. ammoniagenes FAS has been engineered in two cooperatively ...
Isoxazole derivatives as new nitric oxide elicitors in plants
- Anca Oancea,
- Emilian Georgescu,
- Florentina Georgescu,
- Alina Nicolescu,
- Elena Iulia Oprita,
- Catalina Tudora,
- Lucian Vladulescu,
- Marius-Constantin Vladulescu,
- Florin Oancea and
- Calin Deleanu
Beilstein J. Org. Chem. 2017, 13, 659–664, doi:10.3762/bjoc.13.65
- ]. The thiophene is a core system of a large number of bioactive molecules such as antineoplastic agents [49], non-steroidal anti-inflammatory drugs [50] or compounds with antibacterial activities against several Gram-positive strains [51]. Thus, 3,5-disubstituted isoxazole derivatives were obtained by
Graphical Abstract
Scheme 1: Synthetic route to 3,5-disubstituted isoxazoles.
N-Propargylamines: versatile building blocks in the construction of thiazole cores
- S. Arshadi,
- E. Vessally,
- L. Edjlali,
- R. Hosseinzadeh-Khanmiri and
- E. Ghorbani-Kalhor
Beilstein J. Org. Chem. 2017, 13, 625–638, doi:10.3762/bjoc.13.61
- prevent gout flare-ups [5][6][7]. Ritonavir (norvir), is an HIV protease inhibitor. It works by blocking the growth of HIV [8][9]. Tiazofurin is a C-nucleoside analogue with antineoplastic activity and acts by inhibition of the guanosine triphosphate (GTP) biosynthesis through a reduction of PI and PIP
Graphical Abstract
Figure 1: Selected examples of bioactive thiazole derivatives.
Figure 2: Some natural sources of thiazoles.
Figure 3: Some important thiazole-based compounds derived from N-propargylamines.
Scheme 1: The synthesis of thiazole-2-thiones 3 through the thermal cyclocondensation of N-propargylamines 1 ...
Scheme 2: (a) One-pot synthesis of 2-benzylthiazolo[3,2-a]benzimidazoles 6 through a base-catalyzed cascade r...
Scheme 3: (a) Synthesis of 2-iminothiazolidines 11 from N-propargylamines 9 and isothiocyanates 10. (b) Synth...
Scheme 4: (a) Synthesis of 2-aminothiazoles 17 through the reaction of ethyl 4-aminobut-2-ynoate salts 15 wit...
Scheme 5: Synthesis of 5-(iodomethylene)-3-methylthiazolidines 27 described by Zhou.
Scheme 6: Mechanism that accounts for the formation of 27.
Scheme 7: Clausen’s synthesis of fluorescein thiazolidines 30.
Scheme 8: Synthesis of multiply substituted thiazolidines 33 from N-propargylamines 32 and blocked N-isothioc...
Scheme 9: (a) Microwave-assisted cyclization of N-propargyl thiocarbamate 34. (b) Synthesis of thiazoles 39 t...
Scheme 10: Synthesis of thiazolidines 42 (42’) from the reaction of β-oxodithioesters 40 (40’) with N-propargy...
Scheme 11: Synthesis of 5-(dibromomethyl)thiazoles 44 via halocyclization of N-propargylamines 43 described by...
Scheme 12: Synthesis of dihydrothiazoles 46 through the treatment of N-propargylamides 45 with Lawesson’s reag...
Scheme 13: Synthesis of thiazoles 49 by treatment of silyl-protected N-propargylamines 47 with benzotriazolylt...
Scheme 14: Mechanism proposed to explain the synthesis of 2,5-disubstituted thiazoles 49 developed by Sasmal.
Scheme 15: Mo-catalyzed cyclization of N-propargylthiocarbamate 50.
Scheme 16: (a) DABCO-mediated intramolecular cyclization of N-(propargylcarbamothioyl)amides 53 to the corresp...
Scheme 17: Proposed mechanism for the generation of the iodine-substituted 4H-1,3-thiazines 56 and 4,5-dihydro...
Scheme 18: Au(III)-catalyzed synthesis of 5-alkylidenedihydrothiazoles 58 developed by Stevens.
Unconventional application of the Mitsunobu reaction: Selective flavonolignan dehydration yielding hydnocarpins
- Guozheng Huang,
- Simon Schramm,
- Jörg Heilmann,
- David Biedermann,
- Vladimír Křen and
- Michael Decker
Beilstein J. Org. Chem. 2016, 12, 662–669, doi:10.3762/bjoc.12.66
- -methoxyhydnocarpin has been described to enhance the antimicrobial activity of berberine [19]. In the light of steadily growing antibiotic resistance any potent and nontoxic MDR inhibitor is of utmost importance. Hydnocarpin has also antineoplastic activity due to sensitizing multidrug-resistant cancer cell lines
Graphical Abstract
Figure 1: Structures of silibinin, isosilybin, and silychristin, and hydnocarpin-type flavonolignans.
Figure 2: Synthetic strategy of semi-synthesis of hydnocarpins from silybins [22].
Scheme 1: Synthesis of ester derivatives of silibinin and conversion to hydnocarpin-type compounds. Reaction ...
Figure 3: Putative mechanism of dehydration of flavanonols under Mitsunobu conditions.
Scheme 2: Attempt to dehydrate catechin. Reagents and conditions: a) p-nitrobenzoic acid, Ph3P, DIAD, THF, rt...
Scheme 3: Preparation of hydnocarpin (4) and isohydnocarpin (6) and attempt to dehydrate silydianin A (11). R...
Synthesis of cyclic N1-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells
- Ahmed Mahal,
- Stefano D’Errico,
- Nicola Borbone,
- Brunella Pinto,
- Agnese Secondo,
- Valeria Costantino,
- Valentina Tedeschi,
- Giorgia Oliviero,
- Vincenzo Piccialli and
- Gennaro Piccialli
Beilstein J. Org. Chem. 2015, 11, 2689–2695, doi:10.3762/bjoc.11.289
- synthetic building blocks towards the synthesis of biologically relevant compounds such as antiviral and antineoplastic drugs [3][4][5][6][7][8], antibiotics and antifungal agents [9][10][11]. Furthermore, several NNs act as potent second messengers involved in the regulation of key metabolic pathways [12
Graphical Abstract
Figure 1: Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP (4).
Figure 2: Synthetic strategies explored in the cyclization step via phosphodiester bond formation.
Scheme 1: i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iP...
Scheme 2: i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h...
Figure 3: Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representa...
Versatile synthesis and biological evaluation of novel 3’-fluorinated purine nucleosides
- Hang Ren,
- Haoyun An,
- Paul J. Hatala,
- William C. Stevens Jr,
- Jingchao Tao and
- Baicheng He
Beilstein J. Org. Chem. 2015, 11, 2509–2520, doi:10.3762/bjoc.11.272
- ’-fluoro-adenosine 1 in 93% yield. We targeted 9-(3-deoxy-3-fluoro-β-D-ribofuranosyl)purine (1) in particular because it is the 3’-fluorine analogue of nebularine, a naturally occurring antibacterial and antineoplastic agent [42][43]. 3’-Fluoro-6-methylpurine riboside 4, a 6-β-D-MPR mimic 6-Methylpurine-β
- -chloro-intermediates 26 and 48, followed by deprotection, resulted in 6-deaminopurine nucleosides 1 and 21, new analogues of the naturally isolated antibacterial and antineoplastic agent 6-deaminoadenosine, nebularine. Newly synthesized compounds were evaluated for their antitumor activity. Eleven
Graphical Abstract
Figure 1: 6-Subsituted purine 3’-deoxy-3’-fluororibosides 1–15.
Figure 2: 2-Chloro- and 2-aminopurine 3’-deoxy-3’-fluororibosides 16–23.
Figure 3: 3’-Deoxy-3’-fluororibosides constructed from universal intermediate 25.
Scheme 1: Synthesis of 3’-deoxy-3’-fluoropurine ribosides 1–3.
Scheme 2: Synthesis of 6-methylpurine 3’-deoxy-3’-fluororiboside 4.
Scheme 3: Synthesis of 6-substituted purine 3’-deoxy-3’-fluororibosides 5–15.
Scheme 4: Synthesis of 6-substituted 2-chloropurine 3’-deoxy-3’-fluororibosides 16–20.
Scheme 5: Synthesis of 2-aminopurine 3’-deoxy-3’-fluororibosides 21–23.
Dicarboxylic esters: Useful tools for the biocatalyzed synthesis of hybrid compounds and polymers
- Ivan Bassanini,
- Karl Hult and
- Sergio Riva
Beilstein J. Org. Chem. 2015, 11, 1583–1595, doi:10.3762/bjoc.11.174
- in the esterification of the antineoplastic antibiotics mithramycin (5) catalyzed by Candida antarctica lipase A (CAL-A) and chromomycin A3 (6) catalyzed by Candida antarctica lipase B (CAL-B) [24]. In another report a series of mono-substituted troxerutin esters (7a) were synthesized by action of
Graphical Abstract
Scheme 1: Activated derivatives of dicarboxylic acids.
Figure 1: Example of natural compounds selectively acylated with dicarboxylic esters.
Figure 2: C6-dicarboxylic acid diesters derivatives of NAG-thiazoline.
Figure 3: Sylibin dimers obtained by CAL-B catalyzed trans-acylation reactions.
Scheme 2: Biocatalyzed synthesis of paclitaxel derivatives.
Figure 4: 5-Fluorouridine derivatives obtained by CAL-B catalysis.
Scheme 3: Biocatalyzed synthesis of hybrid diesters 17 and 18.
Scheme 4: Hybrid derivatives of sylibin.
Figure 5: Bolaamphiphilic molecules containing (L)- and/or (D)-isoascorbic acid moieties.
Figure 6: Doxorubicin (29) trapped in a polyester made of glycolate, sebacate and 1,4-butandiol units.
Figure 7: Polyesters containing functionalized pentofuranose derivatives.
Figure 8: Polyesters containing disulfide moieties.
Figure 9: Polyesters containing epoxy moieties.
Figure 10: Biocatalyzed synthesis of polyesters containing glycerol.
Figure 11: Iataconic (34) and malic (35) acid.
Figure 12: Oxidized poly(hexanediol-2-mercaptosuccinate) polymer.
Figure 13: C-5-substituted isophthalates.
Figure 14: Curcumin-based polyesters.
Figure 15: Silylated polyesters.
Figure 16: Polyesters containing reactive ether moieties.
Figure 17: Polyesters obtained by CAL-B-catalyzed condensation of dicarboxylic esters and N-substituted dietha...
Figure 18: Polyesters comprising mexiletine (38) moieties.
Figure 19: Poly(amide-co-ester)s comprising a terminal hydroxy moiety.
Figure 20: Polymer comprising α-oxydiacid moieties.
Figure 21: Telechelics with methacrylate ends.
Figure 22: Telechelics with allyl-ether ends.
Figure 23: Telechelics with ends functionalized as epoxides.
DBU-promoted carboxylative cyclization of o-hydroxy- and o-acetamidoacetophenone
- Wen-Zhen Zhang,
- Si Liu and
- Xiao-Bing Lu
Beilstein J. Org. Chem. 2015, 11, 906–912, doi:10.3762/bjoc.11.102
- [4]. Roquinimex was reported as an antineoplastic agent [5]. Traditional methods for accessing these compounds rely heavily on cyclization reactions using diethyl carbonate in the presence of inorganic bases [6][7] or Friedel–Crafts reactions using strong and corrosive acids [8]. In terms of
Graphical Abstract
Figure 1: Selected examples for biologically active 4-hydroxy-2H-chromen-2-one and 4-hydroxy-2(1H)-quinolinon...
Scheme 1: Possible mechanism for the carboxylative cyclization of o-acetamidoacetophenone.
Scheme 2: Cross carboxylative cyclization reaction.
Olefin cross metathesis based de novo synthesis of a partially protected L-amicetose and a fully protected L-cinerulose derivative
- Bernd Schmidt and
- Sylvia Hauke
Beilstein J. Org. Chem. 2014, 10, 1023–1031, doi:10.3762/bjoc.10.102
- antibiotic is aclacinomycin A, which has been used clinically under the name aclarubicin. It is an anthracycline [10] bearing a trisaccharide side chain consisting of L-rhodosamin, 2,6-didesoxy-L-lyxose, and L-cinerulose attached to the aglycon aclavinon [11][12]. It was found to be a potent antineoplastic
- apparently identical catalysts which are often designated just as “10 wt % Pd on carbon” may vary dramatically. Structures of kigamicin B and aclacinomycin A as representative examples for antineoplastic glycoconjugates. RCM-isomerization approach to L-amicetal 4 and alternative CM approaches to L-amicetose
Graphical Abstract
Figure 1: Structures of kigamicin B and aclacinomycin A as representative examples for antineoplastic glycoco...
Scheme 1: RCM-isomerization approach to L-amicetal 4 and alternative CM approaches to L-amicetose.
Scheme 2: Two step desilylation–acetal hydrolysis.
Scheme 3: Deprotection of 11 and 12 to L-amicetose derivative 16.
Scheme 4: Synthesis of a cinerulose-TBS ether 22.
Scheme 5: Deprotection of 24.
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
- Marcus Baumann and
- Ian R. Baxendale
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Engineering of indole-based tethered biheterocyclic alkaloid meridianin into β-carboline-derived tetracyclic polyheterocycles via amino functionalization/6-endo cationic π-cyclization
- Piyush K. Agarwal,
- Meena D. Dathi,
- Mohammad Saifuddin and
- Bijoy Kundu
Beilstein J. Org. Chem. 2012, 8, 1901–1908, doi:10.3762/bjoc.8.220
- in the literature. β-Carbolines are some of the most widely distributed alkaloids, associated with activities ranging from antineoplastic (tubulin binding) [44][45][46], anticonvulsive, hypnotic and anxiolytic (benzodiazepine receptor ligands) [47], antimicrobial as well as topoisomerase-II
Graphical Abstract
Figure 1: Structure of meridianins A–G.
Scheme 1: Synthesis of functionalized meridianin with an amino group at position 5.
Scheme 2: Synthesis of a functionalized meridianin with an amino group at position 5.
Scheme 3: Synthesis of substrate for the modified Pictet–Spengler reaction.
Scheme 4: The Pictet–Spengler reaction involving substrate 2a. Reagents and conditions: (i) RCHO, 2% triflic ...
Scheme 5: Synthesis of dihydropyrimido-β-carbolines: (i) R-CHO, 2% triflic acid in DMF, 120 °C, 16 h.
Scheme 6: Synthesis of substrates 18a–c for the modified Pictet–Spengler reaction.
Scheme 7: General strategy for the Pictet–Spengler reaction involving substrates 18. Reagents and conditions:...
Directed aromatic functionalization in natural-product synthesis: Fredericamycin A, nothapodytine B, and topopyrones B and D
- Charles Dylan Turner and
- Marco A. Ciufolini
Beilstein J. Org. Chem. 2011, 7, 1475–1485, doi:10.3762/bjoc.7.171
- properties of topopyrones are sufficiently interesting that a number of groups embarked on a total synthesis [94][95][96]. Our own involvement in this area was motivated by an interest in topoisomerase-I inhibitors, which are important antineoplastic resources [97], the archetype of which is camptothecin [81
Graphical Abstract
Scheme 1: Structure and retrosynthetic analysis of fredericamycin A.
Scheme 2: Assembly of the isoquinolone segment of fredericamycin.
Scheme 3: Synthesis of a naphthalide precursor to the quinoid moiety of fredericamycin.
Scheme 4: Palladium-mediated cyclization of a fredericamycin model system.
Scheme 5: Synthesis of the precursor of fredericamycin and the facile air oxidation thereof.
Scheme 6: Formal synthesis of fredericamycin A.
Figure 1: Structure of nothapodytine B.
Scheme 7: A useful pyridone synthesis.
Scheme 8: Retrosynthetic logic for nothapodytine B.
Scheme 9: Preparation of a key nothapodytine fragment.
Scheme 10: Total synthesis of nothapodytine B.
Figure 2: Structures of topopyrones.
Scheme 11: Retrosynthetic logic for the linear series of topopyrones.
Scheme 12: Construction of the molecular subunit common to all topopyrones.
Scheme 13: Difficulties encountered during the merger of the topopyrone D moieties.
Scheme 14: Efficient synthesis of a simplified anthraquinone.
Scheme 15: Total synthesis of topopyrone D.
Scheme 16: Total synthesis of topopyrone B.
Synthesis of some novel hydrazono acyclic nucleoside analogues
- Mohammad N. Soltani Rad,
- Ali Khalafi-Nezhad and
- Somayeh Behrouz
Beilstein J. Org. Chem. 2010, 6, No. 49, doi:10.3762/bjoc.6.49
- antineoplastic (e.g. bisantrene [4][10]), contain a hydrazone moiety in their structure. Furthermore, various structurally related miconazole bioactive hydrazones are known as antimicrobial and antifungal agents [11][12]. The significance of nucleoside chemistry in drug discovery is well-known and fully
Graphical Abstract
Figure 1: Chemical structures of miconazole (A), oxiconazole (B) and hydrazono acyclic nucleoside analogue (C...
Scheme 1: Synthetic pathway for hydrazono acyclic nucleoside 2a–2g.
Scheme 2: Synthetic pathway for hydrazono acyclic nucleoside 2h–2o.
